An open-label study was performed to assess the effectiveness of oral azathioprine (AZA) on augmenting the response to interferon β-1b (IFNβ-1b) in patients with treatment-refractory relapsing-remitting MS. Six IFNβ-1b-treated MS patients with continued disease activity were studied on IFNβ-1b and AZA therapy for a median period of 15 months. A 69% reduction in the number of contrast-enhancing lesions was observed during the combination therapy (p = 0.002).
|Original language||English (US)|
|Number of pages||3|
|State||Published - Jun 10 2003|
ASJC Scopus subject areas